BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 38128940)

  • 1. Cohort profile: COBLAnCE: a French prospective cohort to study prognostic and predictive factors in bladder cancer and to generate real-world data on treatment patterns, resource use and quality of life.
    Lebret T; Bonastre J; Fraslin A; Neuzillet Y; Droupy S; Rebillard X; Vordos D; Guy L; Villers A; Schneider M; Coloby P; Lacoste J; Méjean A; Lacoste J; Descotes JL; Eschwege P; Loison G; Blanché H; Mariani O; Ghaleh B; Mangin A; Sirab N; Groussard K; Radvanyi F; Allory Y; Benhamou S
    BMJ Open; 2023 Dec; 13(12):e075942. PubMed ID: 38128940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence and location of lymph node metastases in patients undergoing radical cystectomy for clinical non-muscle invasive bladder cancer: results from a prospective lymph node mapping study.
    Bruins HM; Skinner EC; Dorin RP; Ahmadi H; Djaladat H; Miranda G; Cai J; Daneshmand S
    Urol Oncol; 2014 Jan; 32(1):24.e13-9. PubMed ID: 23395238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective multicenter study on bladder cancer: the COBLAnCE cohort.
    Benhamou S; Bonastre J; Groussard K; Radvanyi F; Allory Y; Lebret T
    BMC Cancer; 2016 Nov; 16(1):837. PubMed ID: 27809812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced Quality and Effectiveness of Transurethral Resection of Bladder Tumour in Non-muscle-invasive Bladder Cancer: A Multicentre Real-world Experience from Scotland's Quality Performance Indicators Programme.
    Mariappan P; Johnston A; Padovani L; Clark E; Trail M; Hamid S; Hollins G; Simpson H; Thomas BG; Hasan R; Bhatt J; Ahmad I; Nandwani GM; Mitchell IDC; Hendry D;
    Eur Urol; 2020 Oct; 78(4):520-530. PubMed ID: 32690321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence and outcomes of transurethral resection versus radical cystectomy for muscle-infiltrating bladder cancer in the United States: A population-based cohort study.
    Zheng Y; Ye Y; Chen J; Wei Z; Liu Z; Yu K; Zhang X
    Int J Surg; 2022 Jul; 103():106693. PubMed ID: 35690361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective Assessment of Vesical Imaging Reporting and Data System (VI-RADS) and Its Clinical Impact on the Management of High-risk Non-muscle-invasive Bladder Cancer Patients Candidate for Repeated Transurethral Resection.
    Del Giudice F; Barchetti G; De Berardinis E; Pecoraro M; Salvo V; Simone G; Sciarra A; Leonardo C; Gallucci M; Catalano C; Catto JWF; Panebianco V
    Eur Urol; 2020 Jan; 77(1):101-109. PubMed ID: 31699526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protocol of the Comparison of Intravesical Therapy and Surgery as Treatment Options (CISTO) study: a pragmatic, prospective multicenter observational cohort study of recurrent high-grade non-muscle invasive bladder cancer.
    Gore JL; Wolff EM; Comstock BA; Follmer KM; Nash MG; Basu A; Chisolm S; MacLean DB; Lee JR; Lotan Y; Porten SP; Steinberg GD; Chang SS; Gilbert SM; Kessler LG; Smith AB;
    BMC Cancer; 2023 Nov; 23(1):1127. PubMed ID: 37980511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Implications of Immunohistochemical Biomarkers in Non-muscle-invasive Blad Cancer and Muscle-invasive Bladder Cancer.
    Boegemann M; Krabbe LM
    Mini Rev Med Chem; 2020; 20(12):1133-1152. PubMed ID: 27173513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.
    Giulianelli R; Gentile BC; Mirabile G; Albanesi L; Tariciotti P; Rizzo G; Buscarini M; Vermiglio M
    Arch Ital Urol Androl; 2017 Dec; 89(4):272-276. PubMed ID: 29473376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the prognosis of primary vs. progressive muscle invasive bladder cancer after radical cystectomy: Results from a large multicenter study.
    Nouhaud FX; Chakroun M; Lenormand C; Ouzaid I; Peyronnet B; Gryn A; Prudhomme T; Grafeille V; Soulié M; Roumiguié M; Verhoest G; Xylinas E; Bouzouita A; Chebil M; Pfister C
    Urol Oncol; 2021 Mar; 39(3):195.e1-195.e6. PubMed ID: 33214030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Results of radical cystectomy for management of invasive bladder cancer with special reference to prognostic factors and quality of life depending on the type of urinary diversion].
    Słojewski M
    Ann Acad Med Stetin; 2000; 46():217-29. PubMed ID: 11712306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy.
    Pietzak EJ; Zabor EC; Bagrodia A; Armenia J; Hu W; Zehir A; Funt S; Audenet F; Barron D; Maamouri N; Li Q; Teo MY; Arcila ME; Berger MF; Schultz N; Dalbagni G; Herr HW; Bajorin DF; Rosenberg JE; Al-Ahmadie H; Bochner BH; Solit DB; Iyer G
    Eur Urol; 2019 Feb; 75(2):231-239. PubMed ID: 30290956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating the cost-utility of intravesical Bacillus Calmette-Guérin versus radical cystectomy in patients with high-risk non-muscle-invasive bladder cancer in the UK.
    Grabe-Heyne K; Henne C; Odeyemi I; Pöhlmann J; Ahmed W; Pollock RF
    J Med Econ; 2023; 26(1):411-421. PubMed ID: 36897006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis.
    Zlotta AR; Ballas LK; Niemierko A; Lajkosz K; Kuk C; Miranda G; Drumm M; Mari A; Thio E; Fleshner NE; Kulkarni GS; Jewett MAS; Bristow RG; Catton C; Berlin A; Sridhar SS; Schuckman A; Feldman AS; Wszolek M; Dahl DM; Lee RJ; Saylor PJ; Michaelson MD; Miyamoto DT; Zietman A; Shipley W; Chung P; Daneshmand S; Efstathiou JA
    Lancet Oncol; 2023 Jun; 24(6):669-681. PubMed ID: 37187202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013.
    Babjuk M; Burger M; Zigeuner R; Shariat SF; van Rhijn BW; Compérat E; Sylvester RJ; Kaasinen E; Böhle A; Palou Redorta J; Rouprêt M;
    Eur Urol; 2013 Oct; 64(4):639-53. PubMed ID: 23827737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Value of multiparametric magnetic resonance imaging for local staging of invasive urinary bladder tumours.
    Huele EH; Veenboer PW; Wessels FJ; Jonges TN; Meijer RP
    Urol Oncol; 2023 Jan; 41(1):49.e7-49.e12. PubMed ID: 36441069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective bladder-sparing protocol consisting of induction low-dose chemoradiotherapy plus partial cystectomy with pelvic lymph node dissection against muscle-invasive bladder cancer: oncological outcomes of the initial 46 patients.
    Koga F; Kihara K; Yoshida S; Yokoyama M; Saito K; Masuda H; Fujii Y; Kawakami S
    BJU Int; 2012 Mar; 109(6):860-6. PubMed ID: 21854531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protocol of the Italian Radical Cystectomy Registry (RIC): a non-randomized, 24-month, multicenter study comparing robotic-assisted, laparoscopic, and open surgery for radical cystectomy in bladder cancer.
    Porreca A; Palmer K; Artibani W; Antonelli A; Bianchi L; Brunocilla E; Bocciardi AM; Brausi M; Busetto GM; Carini M; Carrieri G; Celia A; Cindolo L; Cochetti G; Colombo R; De Berardinis E; De Cobelli O; Di Maida F; Ercolino A; Gaboardi F; Galfano A; Gallina A; Gallucci M; Introini C; Mearini E; Minervini A; Montorsi F; Musi G; Pini G; Schiavina R; Secco S; Serni S; Simeone C; Tasso G; D'Agostino D
    BMC Cancer; 2021 Jan; 21(1):51. PubMed ID: 33430820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathology-based risk stratification of muscle-invasive bladder cancer patients undergoing cystectomy for persistent disease after induction chemoradiotherapy in bladder-sparing approaches.
    Koga F; Fujii Y; Masuda H; Numao N; Yokoyama M; Ishioka J; Saito K; Kawakami S; Kihara K
    BJU Int; 2012 Sep; 110(6 Pt B):E203-8. PubMed ID: 22289431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective tetramodal bladder-preservation therapy, incorporating induction chemoradiotherapy and consolidative partial cystectomy with pelvic lymph node dissection for muscle-invasive bladder cancer: oncological and functional outcomes of 107 patients.
    Kijima T; Tanaka H; Koga F; Masuda H; Yoshida S; Yokoyama M; Ishioka J; Matsuoka Y; Saito K; Kihara K; Fujii Y
    BJU Int; 2019 Aug; 124(2):242-250. PubMed ID: 30811784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.